The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer

Journal of Cancer Research and Therapeutics

Volumn 10, Issue 8, 2014, Pages C307-C309

  Wang, Yan Rong ^a   Yan, Jian Xia ^b   Wang, Li Na ^c  

^a TIANJIN FOURTH CENTRAL HOSPITAL   (China)

^b Wuqing People's Hospital   (China)

^c TIANJIN SECOND PEOPLE S HOSPITAL   (China)

Author keywords

Carbohydrate antigen 19 9; carcino embryonic antigen; colorectal cancer; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; AGED; AREA UNDER THE CURVE; BLOOD; COLORECTAL NEOPLASMS;

ADULT; AGED; ALPHA-FETOPROTEINS; AREA UNDER CURVE; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84924081024     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.151538     Document Type: Article

References (12)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Du M, Liu S, Gu D, Wang Q, Zhu L, Kang M, et al. Clinical potential role of circulating microRNAs in early diagnosis of colorectal cancer patients. Carcinogenesis 2014;35:2723-30.
3. Koness RJ. CEA: is it of value in colorectal cancer? R I Med 1995;78:164-6.
4. Hsieh PS, Changchien CR, Chen JS, Tang R, Chiang JM, Yeh CY, et al. Comparing results of preoperative staging of rectal tumor using endorectal ultrasonography and histopathology. Chang Gung Med J 2003;26:474-8.
5. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104-17.
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
7. Groblewska M, Mroczko B, Gryko M, Kedra B, Szmitkowski M. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients. Folia Histochem Cytobiol 2010;48:564-71.
8. Ishida H, Iwama T, Tomita N, Koizumi K, Akagi K, Ishiguro M, et al. Diagnosis and management of hereditary colorectal cancer according to the JSCCR Guidelines 2012 for the clinical practice of hereditary colorectal cancer. Nihon Rinsho 2014;72:143-9.
9. Legolvan MP, Taliano RJ, Resnick MB. Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: A practical approach. Hum Pathol 2012;43:1157-68.
10. Bei R, Mizejewski GJ. Alpha fetoprotein is more than a hepatocellular cancer biomarker: From spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine. Curr Mol Med 2011;11:564-81.
11. Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O'Brien M, et al. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol 1995;6:581-7.
12. Shiozawa S, Tsuchiya A, Kim DH, Ogawa K. Prognostic significance of CA19-9 levels in patients with pancreatic cancer. Nihon Rinsho 2006;64 Suppl 1:297-300.